Cell-free bioproduction of b-cryptoxanthin and zeaxanthin
US-2024368663-A1 · Nov 7, 2024 · US
P450-BM3 variants with improved activity
US9708587B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9708587-B2 |
| Application number | US-201514794249-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 8, 2015 |
| Priority date | Jul 9, 2014 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.
First claim
Opening claim text (preview).
What is claimed is: 1. A recombinant cytochrome P450-BM3 variant comprising the amino acid sequence of SEQ. ID NO: 16. 2. The recombinant cytochrome P450-BM3 variant of claim 1 , wherein said variant oxidizes an organic substrate selected from the group consisting of nifedipine, propranolol, verapamil, and diclofenac. 3. An isolated polynucleotide comprising, a nucleotide sequence encoding the recombinant cytochrome P450-BM3 variant of claim 1 . 4. The isolated polynucleotide of claim 3 , wherein said nucleotide sequence comprises the nucleotide sequence of SEQ ID NO: 15. 5. An expression vector comprising the polynucleotide of claim 3 . 6. The vector of claim 5 , wherein said polynucleotide is operably linked with regulatory sequences suitable for expression of said polynucleotide sequence in a suitable host cell. 7. The vector of claim 6 , wherein said host cell is a prokaryotic or eukaryotic cell. 8. The vector of claim 7 , wherein said host cell is a prokaryotic cell. 9. The vector of claim 7 , wherein said host cell is Escherichia coli. 10. An isolated host cell comprising the vector of claim 5 . 11. A method for producing at least one a recombinant cytochrome P450-BM3 variant comprising culturing the host cell of claim 10 under conditions such that the recombinant cytochrome P450-BM3 variant is produced. 12. The method of claim 11 , further comprising the step of recovering said recombinant cytochrome P450 variant.
Assignees
Inventors
Classifications
NADPH-hemoprotein reductase (1.6.2.4), i.e. NADP-cytochrome P450-reductase · CPC title
NADPH-cytochrome P450 reductase (1.6.2.4) · CPC title
Unspecific monooxygenase (1.14.14.1) · CPC title
- C12N9/0071Primary
acting on paired donors with incorporation of molecular oxygen (1.14) · CPC title
- C12P13/001Primary
Amines; Imines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9708587B2 cover?
- The present invention provides improved P450-BM3 variants with improved activity. In some embodiments, the P450-BM3 variants exhibit improved activity over a wide range of substrates.
- Who is the assignee on this patent?
- Codexis Inc
- What technology area does this patent fall under?
- Primary CPC classification C12N9/0071. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).